Methods of reversing ticagrelor activity

A method of reversing ticagrelor-associated bleeding, or the risk of said bleeding, in a patient in need thereof comprising administering to said patient a composition comprising an effective amount of a pharmaceutical composition comprising an antibody or fragment thereof that binds to ticagrelor ((1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol) or a metabolite or derivative thereof.